Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

the Cambridge-based company said Wednesday in a statement. While that’s a 6 percent decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to restore ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, Biogen Inc. and Neomorph Inc., are moving forward in the same space in a ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Get ready to uncover the secrets behind Biogen’s success and its pivotal role in shaping the future of healthcare right from Cambridge! Introduction to Biogen and its role in the biotech industry ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ ... and time required to map a human being's genome. Investors in innovation, like Cathie Wood, the CEO of ARK Investment ...

ESOFT Metro Campus has officially launched its Cambridge Authorised Exam Centre, marking a significant milestone in Sri Lanka’s educational landscape. The event featured prominent figures from both ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant ...